TYMS 抗体 (AA 60-174)
Our Local Distributor
北京 101111
Quick Overview for TYMS 抗体 (AA 60-174) (ABIN7875987)
抗原
See all TYMS 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
抗原表位
- AA 60-174
-
原理
- Thymidylate Synthase Antibody
-
纯化方法
- Protein G purified monoclonal antibody
-
免疫原
- A recombinant human protein from within amino acids 60-174 was used as the immunogen for this Thymidylate synthase antibody.
-
亚型
- IgG2c, kappa
-
-
-
-
应用备注
-
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Thymidylate synthase antibody to be titered up or down for optimal performance.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min. -
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- Prediluted in 1X PBS, 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide, *For IHC use only*
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Store the Thymidylate synthase antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
-
-
- TYMS (Thymidylate Synthetase (TYMS))
-
别名
- Thymidylate Synthase
-
背景
- Thymidylate synthase converts deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), which is essential for DNA biosynthesis. Thymidylate synthase is also a critical target for the fluoropyrimidines, an important group of anti-neoplastic drugs that are widely used in the treatment of solid tumors. Both 5-FU and fluorodeoxyuridine are converted in tumor cells to FdUMP which inactivates thymidylate synthase by formation of a ternary covalent complex in the presence of the folate cofactor 5,10-methylenetetrahydrofolate. Expression of thymidylate synthase protein is associated with response to 5-fluorouracil (5-FU) in human colorectal, gastric, head and neck, and breast carcinomas.
-
途径
- Mitotic G1-G1/S Phases
抗原
-